A feasibility study of Psychedelic Microdosing-Assisted Meaning Centred Psychotherapy in advanced stage cancer patients (PAM Trial)
This double-blind, placebo-controlled feasibility trial (n=40) investigates Psychedelic Microdosing-Assisted Meaning-Centred Psychotherapy (PA–MCP) in advanced-stage cancer patients. Led by Dr Lisa Reynolds at The University of Auckland, the study evaluates LSD microdosing (starting at 8 µg, twice weekly for 6 weeks; 13 doses total) alongside Meaning-Centred Psychotherapy.
Details
Randomised, parallel-group, double-blind feasibility trial comparing LSD microdosing plus manualised Meaning-Centred Psychotherapy (7 weekly 1-hour sessions) versus MCP plus matched placebo vials in people with stage IV solid tumours.
Active dosing is sublingual LSD microdoses delivered from single-use vials with a titration protocol (min 4 µg, start 8 µg, max 12 µg) taken twice weekly for a total of 13 occasions; some doses supervised at clinic visits and others self-administered at home; up to seven break-weeks permitted.
Feasibility outcomes include medication adherence, MCP attendance and fidelity, use of break-weeks, recruitment and attrition; sense of meaning assessed with the Personal Meaning Index at baseline, mid- and end-treatment, and at 1- and 6-month follow-up.